RecruitingPHASE2, PHASE3NCT03970447
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
Studying Glioblastoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Global Coalition for Adaptive Research
- Principal Investigator
- Tim Cloughesy, MDGCAR CMO and GBM AGILE Global PI
- Intervention
- Temozolomide(drug)
- Enrollment
- 1280 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2019 – 2030
Study locations (30)
- University of Alabama at Birmingham, Birmingham, Alabama, United States
- University of California, San Diego, La Jolla, California, United States
- Cedars Sinai - Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California, United States
- University of California, Los Angeles, Los Angeles, California, United States
- St. Joseph Hospital, Orange, California, United States
- University of California, San Francisco, San Francisco, California, United States
- Stanford Cancer Center, Stanford, California, United States
- University of Colorado Denver, Aurora, Colorado, United States
- Yale Cancer Center / Smilow Cancer Hospital, New Haven, Connecticut, United States
- Mayo Clinic Cancer Center, Jacksonville, Florida, United States
- Sylvester Comprehensive Cancer Center, Miami, Florida, United States
- Moffitt Cancer Center, Tampa, Florida, United States
- Piedmont Atlanta Hospital, Atlanta, Georgia, United States
- Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
- LSU Health Sciences Center - New Orleans, New Orleans, Louisiana, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
Bayer · Kazia Therapeutics Limited · Kintara Therapeutics, Inc. · Biohaven Pharmaceuticals, Inc. · Vigeo Therapeutics, Inc. · Polaris Group · AstraZeneca
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03970447 on ClinicalTrials.govOther trials for Glioblastoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07501559A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of JL15003 Injection in Patients With Recurrent Glioblastoma (rGBM)Jecho Biopharmaceuticals Co., Ltd.
- RECRUITINGPHASE2NCT07326566Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIIIBlack Diamond Therapeutics, Inc.
- RECRUITINGPHASE1NCT07464925A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade GliomaTetragon Biosciences Ltd
- RECRUITINGNCT07411690Analysis of Cerebrospinal Fluid Leakage After Surgery for Intracranial TumorsMedical University of Warsaw
- RECRUITINGPHASE1NCT07480941Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade GliomaBeijing Biotech
- RECRUITINGPHASE2NCT07225621Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed GlioblastomaAlpheus Medical, Inc.
- RECRUITINGPHASE1, PHASE2NCT073912155G-PEARL: Paxalisib in Malignant Brain TumoursInstitute of Cancer Research, United Kingdom
- RECRUITINGNANCT07426848OT SMILE: Occupational Therapy Group Intervention for Primary Brain Tumour PatientsRoyal College of Surgeons, Ireland